Fate Therapeutics
FATE
181 hedge funds and large institutions have $642M invested in Fate Therapeutics in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 73 increasing their positions, 55 reducing their positions, and 67 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 55
5.85% more ownership
Funds ownership: 108.75% → 114.6% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
21% less funds holding
Funds holding: 228 → 181 (-47)
33% less call options, than puts
Call options by funds: $247K | Put options by funds: $368K
39% less capital invested
Capital invested by funds: $1.06B → $642M (-$418M)
69% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$53.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18M |
| 3 |
D.E. Shaw & Co
New York
|
+$16.3M |
| 4 |
BlackRock
New York
|
+$10.6M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$56.4M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$42.5M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$14M |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$9.16M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$9.15M |
FATE Hedge Fund Activity: Q1 2023 in Review
181 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2023, worth a combined $642M — down 39% from $1.06B a quarter earlier.
Sellers outnumbered buyers: 67 funds closed out of FATE and 21 opened new positions — a net loss of 46 holders — while 55 trimmed existing stakes and 73 added.
The largest buyer was State Street, adding an estimated $53.7M. The largest seller was Capital World Investors, exiting entirely with an estimated $56.4M sold.
- 181 institutional investors held Fate Therapeutics (FATE) as of Q1 2023, down from 228 in Q4 2022.
- Funds reported $642M of Fate Therapeutics stock for Q1 2023, down 39% quarter-over-quarter.
- 21 funds opened new Fate Therapeutics positions in Q1 2023 and 67 closed out, a net change of -46 holders.
- The largest Fate Therapeutics buyer in Q1 2023 was State Street, an estimated $53.7M added.
- The largest Fate Therapeutics seller in Q1 2023 was Capital World Investors, an estimated $56.4M sold.
Based on aggregated 13F filings for Q1 2023.